XOMA Royalty operates within the biomedical industry, and its stock performance was compared to the market index on August 13, 2025.
3 reports, 2 independent
Updated Aug 5
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
XOMA Royalty operates within the biomedical industry, and its stock performance was compared to the market index on August 13, 2025.
How it developed
Newest first. Tap a step to see who reported it.- Zacks Investment Research provided stock analysis and rankings for XOMA Royalty Corporation, a company in the biomedical industry.Sub-event
XOMA Royalty's stock performance was tracked against the market index on August 13, 2025.1 source
Coverage
Newest first; wire copies grouped- ZacksXOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates XOMA Royalty (XOMA) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of a loss of $0.12 per sha
- GlobeNewswireXOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics - Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE